Peripheral neuritis, encompassing inflammation and damage of peripheral nerves, represents a significant global health concern, particularly among older adults and individuals with diabetes. Epidemiological data indicate that approximately 14.6% of the general population is affected, with prevalence rising to nearly 19% in adults aged 61-65, and diabetic peripheral neuropathy contributing substantially to this burden. The chronic nature and functional impact of the condition highlight the urgent need for effective therapies. According to the peripheral neuritis pipeline analysis by Expert Market Research, several promising novel agents and immunotherapies are under clinical development, aiming to address both symptomatic relief and disease-modifying outcomes.
Major companies involved in the peripheral neuritis pipeline analysis include Akeso, and others.
Leading drugs currently in the pipeline include AK135, VMD-3866 Gel, VX-993, and others.
The increasing disease burden from peripheral neuritis, combined with limited effective treatment options and rising healthcare expenditure on chronic neuropathies, is accelerating market growth and stimulating strong investment in novel pipeline therapies.
The Peripheral Neuritis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into peripheral neuritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for peripheral neuritis. The peripheral neuritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peripheral neuritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with peripheral neuritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peripheral neuritis.
Read more about this report - Request a Free Sample
Peripheral neuritis involves inflammation or damage of peripheral nerves, causing pain, tingling, numbness, and functional loss, often linked to diabetes, infections, toxins, or autoimmune conditions. Treatment emphasizes addressing underlying causes, reducing inflammation, and controlling neuropathic pain through agents such as anticonvulsants, antidepressants, and targeted immunotherapies. A major advancement occurred in June 2024, when the U.S. FDA approved VYVGART Hytrulo (efgartigimod + hyaluronidase) for chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated peripheral neuropathy, marking a significant new option for patients requiring sustained disease control.
Peripheral neuritis shows a substantial global burden, with recent estimates indicating an overall peripheral neuropathy prevalence of about 14.6% in the general population, peaking near 19% in adults aged 61-65. Diabetes remains the leading contributor, with diabetic peripheral neuropathy affecting nearly 27% worldwide and rising from 10-15% at diagnosis to over 50% in long-standing disease. Age-related risk is well-established, with prevalence beginning around 10% in middle age, increasing to nearly 40% in older adults, and approaching 50% in individuals above 80, underscoring the combined impact of aging and metabolic disease on peripheral nerve degeneration.
This section of the report covers the analysis of peripheral neuritis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The peripheral neuritis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total peripheral neuritis clinical trials. The report covers Phase I, Phase II, Phase III, Phase IV, and early-phase drugs, providing an in-depth analysis of each drug across these development stages. Phase II accounts for the largest share of peripheral neuritis clinical trials at 48%, reflecting strong mid-stage research activity. Phase III accounts for 27%, highlighting active late-stage development, 4Phase IV represents 4.27%, indicating a smaller proportion of post-marketing studies.
The drug molecule categories covered under the peripheral neuritis pipeline analysis include oligonucleotides, peptides, and small molecules. The peripheral neuritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peripheral neuritis. In September 2025, Lexicon Pharmaceuticals released patient‑reported data underscoring the substantial physical and psychological burden of diabetic peripheral neuropathic pain. Their investigational therapy pilavapadin, a once‑daily, oral, selective small‑molecule inhibitor of AAK1, targets neurotransmitter recycling implicated in pain signaling, offering a non‑opioid approach to neuropathic pain.
The EMR report for the peripheral neuritis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed peripheral neuritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in peripheral neuritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peripheral neuritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peripheral neuritis drug candidates.
AK135 is an investigational antibody developed by Akeso, Inc., targeting IL‑1RAP to block inflammatory signaling pathways involved in chemotherapy-induced peripheral neuropathy. By inhibiting IL‑1, IL‑33, and IL‑36 mediated pathways, AK135 reduces nerve inflammation and pain in preclinical models. Akeso, a clinical-stage biopharmaceutical company, focuses on next-generation immunotherapies and biologics. AK135 represents their expansion into neuro-inflammation, aiming to provide a non-opioid therapeutic option for patients with neuropathic pain, addressing a currently unmet clinical need.
VMD‑3866 Gel, developed by VM Therapeutics LLC, is a topical analgesic designed for chemotherapy-induced peripheral neuropathy. It works by antagonizing calcium channels in peripheral nerves, reducing local hyperexcitability and pain signaling without systemic exposure. VM Therapeutics is a biotech firm developing novel non-opioid pain therapies. The gel formulation offers targeted, localized relief with reduced side effects, providing a promising alternative to oral medications. Ongoing Phase 2 trials are evaluating its safety and efficacy in patients suffering neuropathic pain.
VX‑993, from Vertex Pharmaceuticals, is an oral small-molecule inhibitor of NaV1.8 sodium channels, reducing pain signal transmission in peripheral nerves. Initially developed for acute pain, it is now evaluated for diabetic peripheral neuropathy. Vertex, a global biotech leader known for cystic fibrosis therapies, is expanding into pain and rare disease indications. VX‑993’s non-opioid mechanism aims to provide effective neuropathic pain relief, though its Phase 2 trial in acute pain failed. Ongoing studies focus on chronic neuropathy to determine its therapeutic potential.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Peripheral Neuritis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for peripheral neuritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into peripheral neuritis collaborations, regulatory environments, and potential growth opportunities.
Peripheral Neuritis Epidemiology Forecast
Upto 30% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share